Table 3.
Unit costs (€, 2018)
| Treatment acquisition | Unit cost (€, 2018) | |||
| Therapy | No. of administrations in 6 months | EFP [39] with Royal Decree 08/2010 deduction or reference price | Pharmacological cost of the therapy in combination with MTX, per 6-month period | |
| Initial period | Subsequent periods | |||
| Abatacept 125 mg | 26 | 26 | €194.42 | €5055.06 |
| Adalimumab 40 mg | 13 | 13 | €404.25** | €5255.37 |
| Baricitinib 4 mg | 182 | 182 | €31.08 | €5672.24 |
| Certolizumab 200 mg | 13 | 13 | €438.45 | €5699.99 |
| Etanercept 50 mg | 26 | 26 | €169.07* | €4395.96 |
| Rituximab 500 mg | 1.33 | 1.33 | €970.65** | €1294.34 |
| Tocilizumab 162 mg | 26 | 26 | €225.98 | €5875.62 |
| Tofacitinib 5 mg | 365 | 365 | €13.61 | €4968.05 |
| Methotrexate 2.5 mg | 26 | 26 | €0.05 | - |
| Healthcare resources | Unit cost (€, 2018) | |||
| Training session for subcutaneous self-administration | €27.10 [40] | |||
| Infusion at day hospital | €252.42 [40] | |||
| Initial rheumatologist consultation | €111.52 [40] | |||
| Subsequent rheumatologist consultation | €66.91 [40] | |||
| Severe infection management | €5871.08 [40] | |||
EFP, ex-factory price; MTX, methotrexate
*Reference price
**Lowest price of the biosimilar products available on Spanish market